Biomedical Engineering Reference
In-Depth Information
[126] Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene ther-
apy for the treatment of brain tumors using intra-tumoral transduction with the thymi-
dine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4:39-69.
[127] Klatzmann D, Valery C, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase
I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for
recurrent glioblastoma. Study group on gene therapy for glioblastoma. Hum Gene Ther
1998;9:2595-604.
[128] Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, et al. A
phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor
transduction with the herpes simplex thymidine kinase gene followed by ganciclovir.
Hum Gene Ther 1999;10:2325-35.
[129] Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, et al. Treatment
of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes
simplex virus thymidine kinase gene vector-producer cells followed by intravenous gan-
ciclovir administration. J Neurosurg 2000;92:249-54.
[130] Miller C, Williams C, Buchsbaum D, Gillespie G. Intratumoral 5-fluorouracil produced
by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental
human glioblastomas. Cancer Res 2002;62:773-80.
[131] Manome Y, Wen P, Chen L, Tanaka T, Dong Y, Yamazoe M, et al. Gene therapy for
malignant gliomas using replication incompetent retroviral and adenoviral vectors
encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther
1996;3:513-20.
[132] Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene
therapy. Brain Pathol 1998;8:599-613.
[133] Lang FF, Yung WKA, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for
human gliomas. Neurosurgery 1999;45:1093-104.
[134] Alavi JB, Eck SL. Gene therapy for malignant gliomas. Hematol/Oncol Clin North Am
1998;12:617-29.
[135] Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, et al. Phase I trial
of adenovirus mediated p53 gene therapy for recurrent glioma: biological and clinical
results. J Clin Oncol 2003;21:2508-18.
[136] Inoue R, Moghaddam K, Ranasinghe M, Saeki Y, Chiocca EA, Wade-Martins R. Infectious
delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced
gene expression and growth suppression in glioma cells. Gene Ther 2004;11:1195-204.
[137] Ishida H, Kaneda Y, Yamane S, Sawada T, Plautz GE, Matsumura T. Allogeneic class
I major histocompatibility complex gene transfer in murine neuroblastoma in vivo .
Anticancer Res 1999;19:5367-73.
[138] Wollenberg B, Lang S, Friess T, Naujoks K, Mayer A, Kastenbauer E, et al. Induction
of antitumor immune response in the mouse model after vaccination with B7.1 express-
ing tumor cells. Laryngorhinootologie 1999;78:36-40.
[139] Joki T, Kikuchi T, Akasaki Y, Saitoh S, Abe T, Ohno T. Induction of effective antitumor
immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive
molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int J Cancer
1999;82:714-20.
[140] Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene
transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
J Exp Med 1990;172:1217-24.
[141] Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engi-
neered interleukin 4-secreting cells. Cancer Res 1993;53:3125-8.
Search WWH ::




Custom Search